New Data Validates Health Economic Benefits of Nevro’s High-Frequency Spinal Cord Stimulation Therapy

Nevro Corp., a global medical device company specializing in chronic pain treatment, has recently published data that supports the health economic benefits of their proprietary high-frequency spinal cord stimulation (SCS) therapy, known as 10 kHz Therapy™. The therapy has shown promising results in reducing hospital resource utilization for patients with painful diabetic neuropathy (PDN) and nonsurgical refractory back pain.

A study published in the Journal of Managed Care & Specialty Pharmacy evaluated the impact of 10 kHz Therapy on PDN patients. The results demonstrated that patients receiving the therapy experienced significantly fewer hospitalizations compared to those receiving conventional medical management (CMM). Additionally, the total healthcare costs per patient were approximately 51% lower in the 10 kHz Therapy group.

Another study, published in the Journal of Neurosurgery: Spine, assessed the cost-effectiveness of 10 kHz Therapy for patients with nonsurgical refractory back pain. The analysis revealed that the therapy provided a higher quality of life at a lower average cost per patient compared to conventional medical management. It was predicted to be cost-effective within 2.1 years of treatment.

Furthermore, an analysis published in Neuromodulation evaluated the cost burden of 10 kHz Therapy for patients with chronic refractory low back pain. The study found that the therapy was associated with a significant decrease in total healthcare costs, offsetting device acquisition costs within 27 months.

These publications highlight the positive impact of Nevro’s therapy on both patients and healthcare systems. The data supports the company’s commitment to providing highly effective and cost-efficient treatment options for individuals suffering from chronic pain.

David Caraway, MD, Chief Medical Officer at Nevro, expressed gratitude to the researchers for providing real-world data that can help improve treatment options for patients with refractory PDN. Kevin Thornal, CEO and President of Nevro, emphasized that their therapy is reshaping care for people with chronic pain while reducing costs for patients and health systems.

Nevro’s 10 kHz Therapy has the potential to transform the lives of millions of individuals living with chronic pain. As the company continues to innovate and gather evidence, they remain dedicated to delivering comprehensive solutions that improve patient outcomes and accessibility.

For more information about Nevro and their groundbreaking therapies, visit their website or connect with them on social media platforms.